Breathing Room For BMS In Renal Cancer As Early Tecentriq Data Mixed

20 Feb 2017

• By Sukaina Virji

Latecomer Tecentriq from Roche has been making solid in roads in the lung cancer space, where it has been scrapping it out with Bristol-Myers Squibb's Opdivo and Merck & Co's Keytruda. However, early data with Tecentriq in the renal cell carcinoma (RCC) space are less than impressive. The news will be welcomed by BMS, which has Opdivo approved in advanced RCC.

Roche's Genentech division presented the first results from IMmotion150 Phase II study that was investigating Tecentriq (atezolizumab, a PD-L1 antibody) alone, and in combination with Avastin (bevacizumab) vs standard of care Sutent (sunitinib), in first-line metastatic RCC.

In an ITT analysis, the two Tecentriq arms did not show significant benefit over Sutent. However, when only PD-L1 expressers were considered, then Tecentriq + Avastin arm did show significant...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

29 May 2025

• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

28 May 2025

• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.